Stock NXEN NEXIEN BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Nexien BioPharma, Inc.

Equities

NXEN

US65343D1000

Delayed OTC Markets
Other stock markets
 09:32:08 30/05/2024 pm IST 		5-day change 1st Jan Change
0.0204 USD -2.63% Intraday chart for Nexien BioPharma, Inc. +24.39% -21.24%
15/05 Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
20/02 Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
CI
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
CI
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
AQ
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
CI
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
AQ
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022
CI
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022
CI
Nexien BioPharma, Inc. Auditor Raises 'Going Concern' Doubt
CI
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
AQ
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
CI
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
AQ
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021
CI
NEXIEN BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
Nexien BioPharma, Inc. announced that it has received $0.15 million in funding from Quick Capital, LLC
CI
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
AQ
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NXEN Stock
  4. News Nexien BioPharma, Inc.